Genfit (NASDAQ:GNFT) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Genfit (NASDAQ:GNFTGet Rating) from a buy rating to a hold rating in a research note published on Friday morning, Zacks.com reports.

According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “

GNFT has been the topic of a number of other reports. HC Wainwright upgraded Genfit from a neutral rating to a buy rating and set a $8.00 price objective on the stock in a research report on Monday, December 20th. Oddo Bhf raised Genfit to a buy rating in a research note on Friday, December 17th. Finally, SVB Leerink cut their price target on Genfit from $15.00 to $10.00 and set an outperform rating on the stock in a research note on Monday, April 11th.

Shares of GNFT opened at $4.04 on Friday. The company has a current ratio of 4.27, a quick ratio of 4.27 and a debt-to-equity ratio of 0.60. The business’s fifty day moving average price is $3.87 and its two-hundred day moving average price is $3.93. Genfit has a 52 week low of $3.01 and a 52 week high of $6.38.

Hedge funds have recently bought and sold shares of the company. Credit Suisse AG acquired a new position in shares of Genfit in the 4th quarter valued at $55,000. OLD Mission Capital LLC acquired a new position in shares of Genfit in the 3rd quarter valued at $213,000. Morgan Stanley raised its stake in Genfit by 76.7% during the 1st quarter. Morgan Stanley now owns 64,071 shares of the company’s stock worth $296,000 after buying an additional 27,818 shares during the period. Finally, Millennium Management LLC raised its stake in Genfit by 23.3% during the 4th quarter. Millennium Management LLC now owns 392,517 shares of the company’s stock worth $1,963,000 after buying an additional 74,068 shares during the period. 1.22% of the stock is currently owned by institutional investors.

Genfit Company Profile (Get Rating)

Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis.

See Also

Get a free copy of the Zacks research report on Genfit (GNFT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.